Fundraising FoxCellVax Therapeutics
Miami, US · Founded 2020 · Delaware corporation
Find your way into CellVax Therapeutics
Sign up to see every warm intro you have to CellVax Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the CellVax Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
CellVax Therapeutics is a clinical-stage company developing personalized cell-based cancer immunotherapy that converts a patient's own tumor cells into antigen-presenting "Tumor Presenting Cells" to trigger a multi-neoantigen immune response. Its lead product, FK-PC101, targets high-risk prostate cancer patients after prostatectomy, with a platform intended to extend to other solid tumors.
Founders & leadership
CellVax Therapeutics was founded in 2020 by Fernando Kreutz.
FK
Fernando KreutzFounder & CEO, Board of DirectorsFernando Kreutz holds a PhD in Biotechnology from the University of Alberta and an MD from the Federal University of Rio Grande do Sul. He is founder and CEO of CellVax Therapeutics, where he leads clinical development of personalized cancer immunotherapies, and brings over 25 years of experience in immunotherapy, cell therapy, and biotechnology commercialization across multiple therapeutic areas including oncology and vaccine development.
EV
Emerson von der GoltzCFO, Board of DirectorsCFO at CellVax Therapeutics, Emerson von der Goltz is an investment banker with over 15 years in mergers and acquisitions, previously serving as a biotech CFO and ten-year member of an infrastructure equity fund investment committee, with expertise spanning corporate finance, debt raising, and financial modeling across pharmaceuticals, biotechnology, and renewable energy sectors.
Board
AS
Alberto SteinMedical Adviser, Board of Directors
Reported raises · per SEC filings
Form D private placements$2.1M disclosed across 1 round · 2024
▶$2.1MraisedOct 2024 · 1 investors · OtherRule 506(b)
▶$2.1MraisedOct 2024 · 1 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Fernando KreutzExecutive Officer, Director
- Alberto da Costa SteinDirector
- Offering amount
- $5M
- Amount sold
- $2.1M
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 7
DynavaxDynavax is a commercial-stage biopharmaceutical company that develops and commercializes vaccines against infectious diseases using its adjuvant technology. Its products target immunization and infectious disease prevention.
CancerVAXCancerVax develops cancer therapeutics using lipid nanoparticle technology in partnership with Cytiva. The company is focused on creating nanoparticle-based treatments for cancer patients.
MimiVax, LLCMimiVax is a biopharmaceutical company developing immunotherapies for brain tumors, particularly glioblastoma, by harnessing the immune system to target cancer cells. The company's lead candidate, SurVaxM, is a peptide-based vaccine targeting survivin in cancer cells across multiple indications including glioblastoma, multiple myeloma, and neuroendocrine tumors.
CentivaxCentivax is a biotechnology company developing broad-spectrum vaccines, including a universal influenza vaccine.
ImvaxImvax is a clinical-stage biopharmaceutical company developing personalized immunotherapies aimed at treating solid tumors, including glioblastoma. Its platform draws on autologous, cell-based approaches to target cancer.
AbivaxAbivax develops obefazimod, an orally administered small molecule drug candidate with a novel mechanism of action targeting microRNA biology to treat chronic inflammatory diseases including ulcerative colitis and Crohn's disease.
VaccinexVaccinex is a clinical-stage biotechnology company developing pepinemab (VX15/2503), a humanized monoclonal antibody that blocks SEMA4D signaling, in trials for neurological disorders such as Huntington's and Alzheimer's disease and for solid tumors including breast cancer, melanoma, non-small cell lung cancer and head and neck cancer. It also offers a fusion protein and ActivMab antibody discovery technology for incorporating membrane proteins such as GPCRs and ion channels into poxviruses for antibody selection.
Companies working in the same space as CellVax Therapeutics.
Frequently asked questions
- What does CellVax Therapeutics do?
- CellVax Therapeutics is a clinical-stage company developing personalized cell-based cancer immunotherapy that converts a patient's own tumor cells into antigen-presenting "Tumor Presenting Cells" to trigger a multi-neoantigen immune response. Its lead product, FK-PC101, targets high-risk prostate cancer patients after prostatectomy, with a platform intended to extend to other solid tumors.
- Who founded CellVax Therapeutics?
- CellVax Therapeutics was founded by Fernando Kreutz in 2020.
- How much funding has CellVax Therapeutics raised?
- CellVax Therapeutics has disclosed $2.1M raised across 1 round.
- Where is CellVax Therapeutics headquartered?
- CellVax Therapeutics is headquartered in Miami, US.